ArticleBMC veterinary research2026
Protective effect of Lactococcus lactis NZ9000 secreting Bcl2 against Trichinella spiralis infection in mice.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundTrichinellosis, a globally distributed zoonosis, threatens both human health and livestock productivity. The limited efficacy of existing anthelmintics underscores the need for innovative strategies to control Trichinella spiralis infection.
resultsA recombinant food-grade Lactococcus lactis strain (NZ-Bcl2) was engineered to secrete the anti-apoptotic protein Bcl2 by fusing the Bcl2 gene to the Usp45 signal peptide. Western blotting confirmed successful expression and secretion. NZ-Bcl2 strains exhibited stable growth, maintained plasmid inheritance over 24 generations without antibiotic pressure, and persisted in the murine intestine for at least seven days. In low-dose infections (150 larvae/mouse), oral administration of NZ-Bcl2 significantly reduced muscle larval burden, mitigated intestinal damage, and alleviated mesenteric lymph node enlargement. These protective effects were associated with downregulation of pro-inflammatory cytokines (IL-1β, TNF-α), upregulation of anti-inflammatory cytokines (IL-10, TGF-β), and increased expression of intestinal barrier markers (claudin-3, MUC-1). Under high-dose challenge (600 larvae/mouse), the protective effects were attenuated.
conclusionRecombinant L. lactis secreting Bcl2 confers partial protection against T. spiralis by enhancing mucosal barrier function and modulating host immunity. These findings highlight the potential of engineered probiotics as a novel platform for antiparasitic intervention, offering translational relevance for food safety and zoonotic disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.